All HHS Contracts — February 19, 2026

$53.2M obligation with 82% ($43.4M) outlayed supports predictable revenue through 2026; enhances federal IT consulting footprint.

Reliance on 7 subawards totaling $5.9M for delivery order performance.

Short performance period ends Feb 2026 with minimal $0.6M options; tied to parent vehicle funding.

Potential $0.6M option exercise to hit $53.7M ceiling and follow-on CSOM modernization work at FDA.

Large labor-hours delivery order under PSC R703 highlights HHS priority on systems ops for biologics regulation.

{"entity"=>"Deloitte Consulting LLP", "reason"=>"High outlay pace on $53M FDA order indicates revenue visibility; subawards and expiry pose tests.", "trigger"=>"Q4 2025 outlay >90% or follow-on RFP release"}

{"entity"=>"FDA CBER CSOM Program", "reason"=>"Systems modernization spend concentration signals multi-year pipeline.", "trigger"=>"New obligations >$50M or extension announcements"}